| Title |
<p>N-Acetylcysteine to Combat COVID-19: An Evidence Review</p>
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, November 2020
|
| DOI | 10.2147/tcrm.s273700 |
| Pubmed ID | |
| Authors |
Zhongcheng Shi, Carlos A Puyo |
Twitter Demographics
The data shown below were collected from the profiles of 2,696 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 449 | 17% |
| France | 72 | 3% |
| United Kingdom | 64 | 2% |
| Canada | 51 | 2% |
| Spain | 38 | 1% |
| Italy | 37 | 1% |
| Australia | 29 | 1% |
| Brazil | 29 | 1% |
| Poland | 26 | <1% |
| Other | 228 | 8% |
| Unknown | 1673 | 62% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2524 | 94% |
| Practitioners (doctors, other healthcare professionals) | 89 | 3% |
| Scientists | 58 | 2% |
| Science communicators (journalists, bloggers, editors) | 14 | <1% |
| Unknown | 11 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 282 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 282 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 47 | 17% |
| Researcher | 30 | 11% |
| Student > Master | 22 | 8% |
| Other | 21 | 7% |
| Student > Doctoral Student | 15 | 5% |
| Other | 45 | 16% |
| Unknown | 102 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 52 | 18% |
| Nursing and Health Professions | 27 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 26 | 9% |
| Biochemistry, Genetics and Molecular Biology | 19 | 7% |
| Agricultural and Biological Sciences | 13 | 5% |
| Other | 30 | 11% |
| Unknown | 115 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2025. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2023.
All research outputs
#4,308
of 24,554,073 outputs
Outputs from Therapeutics and Clinical Risk Management
#2
of 1,308 outputs
Outputs of similar age
#231
of 426,767 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#2
of 17 outputs
Altmetric has tracked 24,554,073 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 426,767 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.